cancers-logo

Journal Browser

Journal Browser

Lymph Node Detection in Gynecological Cancers

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Causes, Screening and Diagnosis".

Deadline for manuscript submissions: closed (30 June 2025) | Viewed by 274

Special Issue Editor


E-Mail Website
Guest Editor
Department of Gynecology and Obstetrics, University of Parma, Via Gramsci, 14, 43125 Parma, Italy
Interests: gynecologic oncology; gynecologic surgery; laparoscopy; robotic surgery; cytore-ductive surgery
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues,

Nodal staging holds a pivotal role in the treatment and prognostic evaluation of gynecological malignancies. The adoption of sentinel node biopsy (SLN) has revolutionized our surgical approach, significantly impacting the containment of surgical morbidity and providing greater detail in patient prognostication.

Concerning the SLN application, this technique is now the standard in endometrial cancer surgical staging, with high accuracy that has led to its adoption even in high-risk patients.

In 2023, the most recent guidelines on cervical cancer treatment mentioned its adoption, and, even though a pelvic lymphadenectomy is still recommended for stages higher than IA, we expect the results of SENTICOL III to provide further evidence for its use in higher stages. In vulvar cancer, the adoption of SLN can spare fragile and elderly patients from an invasive inguinal lymphadenectomy. However, a double injection procedure with a radiotracer and dye is still the standard, and advancements in this context would be beneficial.

The detection of low-volume metastasis through SLN analysis has provided further detail to surgical staging; however, the prognostic impact of especially isolated tumor cells is still debated. Moreover, the need for adjuvant treatment and the best method of administration are controversial in some contexts.

Advancements in the analysis of SLN include not only ultra-staging and immunohistochemistry but also one-step nucleic acid amplification (OSNA), inherited from breast cancer, which represents an additional innovation in this field. However, more evidence about its applicability and safety in gynecological malignancies is needed.

We cordially invite submissions from experts in the field, especially those focusing on the clinical application of sentinel node biopsy, tracers’ injection techniques, detection of low-volume metastasis, and their impact on patient prognostication.

Sincerely,

Dr. Roberto Berretta
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • sentinel node
  • endometrial cancer
  • cervical cancer
  • vulvar cancer
  • nodal staging
  • ultra-staging
  • isolated tumor cells
  • micrometastasis
  • nodal staging

Benefits of Publishing in a Special Issue

  • Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
  • Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
  • Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
  • External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
  • Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.

Further information on MDPI's Special Issue policies can be found here.

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:

Research

17 pages, 588 KiB  
Article
Serum Levels of CA125 and HE4 as a Tool for Predicting Regional Lymph Node Metastatic Involvement in Endometrial Carcinoma
by Tomáš Crha, Petra Ovesná, Vít Weinberger, Michal Felsinger, Branislav Babjak, Dalibor Valík, Jitka Hausnerová and Luboš Minář
Cancers 2025, 17(17), 2740; https://doi.org/10.3390/cancers17172740 (registering DOI) - 23 Aug 2025
Abstract
Background: Endometrial carcinoma is the most common gynaecological malignant tumour in developed countries. At present, no routinely used serum biomarker is available for the prediction of lymph node metastasis (LNM). This study thus evaluates the potential of tumour markers CA125 and HE4 [...] Read more.
Background: Endometrial carcinoma is the most common gynaecological malignant tumour in developed countries. At present, no routinely used serum biomarker is available for the prediction of lymph node metastasis (LNM). This study thus evaluates the potential of tumour markers CA125 and HE4 as LNM predictors in endometrial carcinoma patients. Objectives: The aim of this study was to evaluate the potential use of CA125 and HE4 and to assess the viability of a model developed using the parameters of serum tumour marker levels for LNM risk stratification. Methods: A retrospective, single-institution study of 220 patients with biopsy-proven endometrial carcinoma was conducted from May 2020 to December 2023. Preoperative serum levels of HE4 and CA125 were determined. All patients underwent surgical lymph node staging. The study evaluated the sensitivity and specificity of tumour markers and of the developed LNM risk prediction model. Results: No LNM was observed in 167 of the 220 patients (75.9%), micrometastatic lymph node involvement was observed in 13 patients (5.9%), and macrometastatic involvement was observed in 24 patients (10.9%). Median CA125 and HE4 levels were significantly higher in patients with LNM than in those without. With a CA125 cut-off value of 35 IU/mL, a sensitivity of 70% and a specificity of 92% were obtained, while an HE4 cut-off value of 103 pmol/L yielded a sensitivity of 78% and a specificity of 80%. A prediction model combining CA125, HE4, and the extent of uterine invasion, as detected by ultrasound, yielded a sensitivity of 84% and a specificity of 98% in predicting LNM. Conclusions: CA125 and HE4, along with the prediction model, facilitate endometrial carcinoma patient subdivision into low- and high-risk LNM groups. As this method is technically simple, non-invasive, and inexpensive, it could be of undeniable benefit in the risk stratification of patients with multiple comorbidities, which limit the duration and extent of surgery. Full article
(This article belongs to the Special Issue Lymph Node Detection in Gynecological Cancers)
Show Figures

Figure 1

Back to TopTop